Cellosaurus logo
expasy logo

Cellosaurus Hep 3B2.1-7 (CVCL_0326)

[Text version]
Cell line name Hep 3B2.1-7
Synonyms Hep 3B2_1-7; Hep 3B 2.1-7; HEP3B217; Hep 3B2; HEP-3B2; HEP3B2; Hep-3B; HEP-3B; Hep 3B; Hep3B; HEP3B
Accession CVCL_0326
Resource Identification Initiative To cite this cell line use: Hep 3B2.1-7 (RRID:CVCL_0326)
Comments Group: Patented cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JFCR45 cancer cell line panel.
Part of: Liver Cancer Model Repository (LIMORE).
Part of: MD Anderson Cell Lines Project.
Part of: TCGA-110-CL cell line panel.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8064.
Population: African American.
Doubling time: 28.05 hours (PubMed=31378681); ~40-50 hours (DSMZ=ACC-93).
Karyotypic information: Has lost chromosome Y.
Microsatellite instability: Stable (MSS) (Sanger).
Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: Hep_3B1_1-7; Cosmic=2773181.
Derived from site: In situ; Liver; UBERON=UBERON_0002107.
Sequence variations
  • Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (PubMed=31395879; Cosmic-CLP=1240147; DepMap=ACH-000625).
  • Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (PubMed=31395879; Cosmic-CLP=1240147; DepMap=ACH-000625).
Genome ancestry Source: PubMed=30894373

Origin% genome
African71.82
Native American0.52
East Asian, North3.16
East Asian, South0
South Asian0
European, North8.8
European, South15.69
Disease Childhood hepatocellular carcinoma (NCIt: C7955)
Pediatric hepatocellular carcinoma (ORDO: Orphanet_33402)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_B6FG (F6D2)CVCL_C8YA (Hep 3B-Luc)CVCL_C8Q9 (Hep3B-c1)
CVCL_XE51 (Hep3b-Cas9-741)CVCL_XE52 (Hep3b-Cas9-742)CVCL_XE53 (Hep3b-Cas9-743)
CVCL_XE54 (Hep3b-Cas9-744)CVCL_XE55 (Hep3b-Cas9-745)CVCL_DI39 (Hep3BLAP-I)
CVCL_DI40 (Hep3BLAP-II)CVCL_DI41 (Hep3BLIP-I)CVCL_DI42 (Hep3BLIP-II)
CVCL_W815 (REPC)CVCL_D9W5 (Ubigene Hep 3B2.1-7 LZTR1 KO)CVCL_D9W6 (Ubigene Hep 3B2.1-7 NR1H4 KO)
Sex of cell Male
Age at sampling 8Y
Category Cancer cell line
STR profile Source(s): AddexBio=C0015001/45; ATCC=HB-8064; CCRID; Cosmic-CLP=1240147; DSMZ=ACC-93; ECACC=86062703; KCLB=88064; PubMed=24116068; PubMed=25877200; PubMed=31378681

Markers:
AmelogeninX
CSF1PO8
D2S133821,25
D3S135815
D5S81813
D7S8208,10
D8S117912
D13S31712,14
D16S53910
D18S5120
D19S43312.2,14
D21S1130,31
FGA18
Penta D12,14
Penta E5,16 (ATCC=HB-8064; CCRID; PubMed=25877200)
16 (DSMZ=ACC-93)
TH016,7
TPOX9
vWA17

Run an STR similarity search on this cell line
Web pages https://www.quora.com/What-is-a-Hep-3B-cell-line
https://lccl.zucmanlab.com/hcc/cellLines/Hep3B
https://tcpaportal.org/mclp/
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-106.html
Publications

PubMed=233137; DOI=10.1038/282615a0
Aden D.P., Fogel A., Plotkin S.A., Damjanov I., Knowles B.B.
Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.
Nature 282:615-616(1979)

PubMed=6248960; DOI=10.1126/science.6248960
Knowles B.B., Howe C.C., Aden D.P.
Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.
Science 209:497-499(1980)

PubMed=6275024; DOI=10.1099/0022-1317-57-1-95
Koshy R., Maupas P., Muller R., Hofschneider P.H.
Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.
J. Gen. Virol. 57:95-102(1981)

PubMed=6288577; DOI=10.1002/ijc.2910300106
Simon D., Aden D.P., Knowles B.B.
Chromosomes of human hepatoma cell lines.
Int. J. Cancer 30:27-33(1982)

Patent=US4393133
Knowles B.B., Aden D.P.
Human hepatoma derived cell line, process for preparation thereof, and uses therefor.
Patent number US4393133, 12-Jul-1983

PubMed=3023526; DOI=10.1099/0022-1317-67-11-2315
Aspinall S., Alexander J.J., Bos P.
Comparative expression of hepatitis B virus antigens in several cell model systems.
J. Gen. Virol. 67:2315-2323(1986)

DOI=10.1007/978-4-431-68349-0_4
Alexander J.J.
Human hepatoma cell lines.
(In book chapter) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo; Japan (1987)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.-J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)

PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613
Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.
FASEB J. 7:1407-1413(1993)

PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x; PMCID=PMC1534706
Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.
HLA expression in hepatocellular carcinoma cell lines.
Clin. Exp. Immunol. 97:328-333(1994)

PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A
Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-i., Teruya K., Kosaka T., Tsuji T., Namba M.
Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.
J. Med. Virol. 48:133-140(1996)

DOI=10.11418/jtca1981.16.3_173
Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ohashi R., Namba M.
The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.
Tissue Cult. Res. Commun. 16:173-178(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9359923; DOI=10.18926/AMO/30789
Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ishioka C., Namba M.
Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.
Acta Med. Okayama 51:261-265(1997)

PubMed=10523694; DOI=10.3892/or.6.6.1267
Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.
Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.
Oncol. Rep. 6:1267-1271(1999)

PubMed=11050057; DOI=10.1053/jhep.2000.19349
Wong N., Lai P., Pang E., Leung T.W.-T., Lau J.W.-Y., Johnson P.J.
A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.
Hepatology 32:1060-1068(2000)

PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=20937217; DOI=10.1170/149
Di Masi A., Viganotti M., Antoccia A., Magrelli A., Salvatore M., Azzalin G., Tosto F., Lorenzetti S., Maranghi F., Mantovani A., Macino G., Tanzarella C., Taruscio D.
Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta-catenin pathway, microRNA expression and protein expression profile.
Cell. Mol. Biol. 56:OL1299-OL1317(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z., Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.-C.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218; PMCID=PMC3731665
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218.1-2218.7(2013)

PubMed=24116068; DOI=10.1371/journal.pone.0075692; PMCID=PMC3792989
Weiskirchen R., Weimer J., Meurer S.K., Kron A., Seipel B., Vater I., Arnold N., Siebert R., Xu L.-M., Friedman S.L., Bergmann C.
Genetic characteristics of the human hepatic stellate cell line LX-2.
PLoS ONE 8:E75692-E75692(2013)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311; PMCID=PMC4284350
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29610054; DOI=10.1016/j.dmpk.2018.03.003; PMCID=PMC6309175
Shi J., Wang X.-W., Lyu L.-Y., Jiang H., Zhu H.-J.
Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes.
Drug Metab. Pharmacokinet. 33:133-140(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001
Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Gastroenterology 157:760-776(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001; PMCID=PMC7505724
Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.
A pharmacogenomic landscape in human liver cancers.
Cancer Cell 36:179-193.e11(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32899426; DOI=10.3390/cancers12092510; PMCID=PMC7565451
Scherer D., Davila-Lopez M., Goeppert B., Abrahamsson S., Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D., Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.
RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling.
Cancers (Basel) 12:2510.1-2510.14(2020)

PubMed=34320349; DOI=10.1016/j.celrep.2021.109441; PMCID=PMC8333195
Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K., Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L., Leite de Oliveira R., Wessels L.F.A., Bernards R.
The cancer SENESCopedia: a delineation of cancer cell senescence.
Cell Rep. 36:109441.1-109441.22(2021)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0015001/45
ATCC; HB-8064
BCRC; 60434
BCRJ; 0357
CCTCC; GDC0070
CLS; 305141
DSMZ; ACC-93
ECACC; 86062703
IZSLER; BS TCL 78
KCB; KCB 200771YJ
KCB; KCB 200942YJ
KCLB; 88064
RCB; RCB2090 - Discontinued
TKG; TKG 0291
Ubigene; YC-D002
Cell line databases/resources CLO; CLO_0003702
CLO; CLO_0003703
CLO; CLO_0003710
MCCL; MCC:0000221
CLDB; cl1627
CLDB; cl1628
CLDB; cl1629
CLDB; cl1630
cancercelllines; CVCL_0326
CCRID; 1101HUM-PUMC000376
CCRID; 1101HUM-PUMC000474
CCRID; 1102HUM-NIFDC00059
CCRID; 3101HUMSCSP5045
CCRID; 3101HUMTCHu106
CCRID; 4201HUM-CCTCC00070
Cell_Model_Passport; SIDM00672
CGH-DB; 454-3
CGH-DB; 9069-4
Cosmic-CLP; 1240147
DepMap; ACH-000625
DSMZCellDive; ACC-93
IGRhCellID; Hep3B
LIMORE; Hep3B
LINCS_LDP; LCL-1924
Lonza; 473
TOKU-E; 1439
TOKU-E; 3574
Anatomy/cell type resources BTO; BTO:0000972
Biological sample resources BioSample; SAMN03473193
BioSample; SAMN10988098
CRISP screens repositories BioGRID_ORCS_Cell_line; 810
Chemistry resources ChEMBL-Cells; CHEMBL4106361
ChEMBL-Targets; CHEMBL4296437
GDSC; 1240147
PharmacoDB; Hep3B2_17_538_2019
PubChem_Cell_line; CVCL_0326
Encyclopedic resources Wikidata; Q54882746
Experimental variables resources EFO; EFO_0002205
EFO; EFO_0022386
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM207050
GEO; GSM501778
GEO; GSM565879
GEO; GSM887078
GEO; GSM888148
GEO; GSM936759
GEO; GSM1374531
GEO; GSM1669879
GEO; GSM2551564
Polymorphism and mutation databases Cosmic; 873401
Cosmic; 928140
Cosmic; 934549
Cosmic; 948066
Cosmic; 979729
Cosmic; 999851
Cosmic; 1019316
Cosmic; 1177682
Cosmic; 1351510
Cosmic; 1518225
Cosmic; 1628385
Cosmic; 2023864
Cosmic; 2162536
Cosmic; 2301557
Cosmic; 2321030
Cosmic; 2668282
Cosmic; 2816904
Cosmic; 2773181
IARC_TP53; 30036
LiGeA; CCLE_655
Progenetix; CVCL_0326
Proteomic databases PRIDE; PXD000533
PRIDE; PXD000535
PRIDE; PXD005291
PRIDE; PXD008190
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number48